Prevention of Vascular Inflammation by Nanoparticle Targeting of Adherent Neutrophils

Zhenjia Wang\textsuperscript{1,2,+}, Jing Li\textsuperscript{1}, Jaehyung Cho\textsuperscript{1,2,3}, and Asrar B. Malik\textsuperscript{1,2,*}

\textsuperscript{1}Department of Pharmacology, \textsuperscript{2}Center for Lung and Vascular Biology, and \textsuperscript{3}Department of Anesthesiology, The University of Illinois Chicago College of Medicine, Chicago, IL 60612

+ Present address: Department of Pharmaceutical Sciences, Washington State University, Spokane, WA

* To whom correspondence should be addressed:

Asrar B. Malik, email: abmalik@uic.edu
Adhesion of polymorphonuclear neutrophils to the vascular endothelium and unchecked neutrophil transmigration are key underlying causes of acute inflammatory diseases such as acute lung injury and ischemic tissue injury\textsuperscript{1,2}. Nanoparticle-mediated targeting\textsuperscript{3} of activated neutrophils on vascular endothelial cells at site of injury may be a useful means of directly inactivating neutrophil transmigration, and hence mitigating vascular inflammation. Here we report the development of a method employing drug-incorporated albumin nanoparticles that efficiently delivered drugs into neutrophils adherent on the surface of the inflamed endothelium. Employing intravital microscopy of tumour necrosis factor-\textalpha\-inflamed cremaster venules in live mice, we demonstrated that fluorescently-tagged albumin nanoparticles with a mean diameter of 100 nm were internalized largely by neutrophils adherent to the activated endothelium through signaling activated by cell surface Fc\textgamma\ receptors. Administration of albumin nanoparticles loaded with the spleen tyrosine kinase inhibitor, piceatannol, which blocks ‘outside-in’ \( \beta \)2 integrin signaling in leukocytes, detached the adherent neutrophils and elicited their release into the circulation. Thus, internalization of drug-loaded albumin nanoparticles into neutrophils inactivates pro-inflammatory signaling of activated neutrophils, thereby offering a promising approach for treating inflammatory diseases resulting from inappropriate neutrophil sequestration and activation.

Neutrophil adhesion to activated endothelial cells and trans-endothelial migration of these cells are essential events of the innate immune response required for kill invading pathogens and bacterial clearance\textsuperscript{4-6}. While neutrophil recruitment into site of injury is
the first-line of defense, excessive neutrophil infiltration and activation at the vessel wall is also the primary cause of inflammation and tissue damage. Neutrophils have been implicated in numerous inflammatory diseases such as acute lung injury, sepsis, and ischemia-reperfusion injury\textsuperscript{1,2,6,7}. Studies showed that inhibition of $\beta_2$ integrins using anti-$\beta_2$ integrin antibodies blocked adhesion of neutrophils to endothelial cells, and prevented inflammation leading to restored vascular integrity\textsuperscript{8}. These studies supported the concept that targeting neutrophils is a useful strategy; however, antibodies have the disadvantage that they induce generalized loss of neutrophil bactericidal function by impairing the ability of circulating neutrophils to adhere and migrate to the infected site\textsuperscript{9}.

Nanoparticles have capabilities to carry and deliver therapeutics to desired cells, based on coating of ligands and antibodies to the their surface\textsuperscript{3,10}. For example, promising results have been obtained using nanoparticles for delivery to therapeutics into tumour cells using cell surface antigens as targeting “addresses”\textsuperscript{11,12}. In this report, using real-time intravital microscopy of inflamed post-capillary venules of live mice, the primary site of neutrophil adhesion and extravasation in the circulation\textsuperscript{13,14}, we demonstrate that albumin nanoparticles are internalized by activated neutrophils through endocytosis that is in part mediated by Fc$\gamma$ receptor III (Fc$\gamma$RIII). Treatment of mice with albumin nanoparticles incorporating piceatannol, an inhibitor for spleen tyrosine kinase (Syk), which blocks ‘outside-in’ integrin signaling\textsuperscript{15}, markedly reduced neutrophil adhesion and migration across the endothelium. Studies in the mouse model of endotoxin-induced acute lung injury mediated by the infiltration of neutrophils also showed that piceatannol-incorporated albumin nanoparticles prevented lung injury.
We first prepared stable albumin nanoparticles by desolvation of bovine serum albumin (BSA) using ethanol, followed by albumin cross-linking using glutaraldehyde (Supplementary Fig. S1)\textsuperscript{16}. To study internalization properties of albumin nanoparticles by phagocytes, we incorporated fluorescent dyes in nanoparticles (Supplementary Fig. S1). Studies using transmission electron microscopy (Supplementary Fig. S2) and dynamic light scattering (Supplementary Fig. S3) showed that the size of albumin nanoparticles with and without fluorescent dyes was similar with mean diameter of 100 ± 10 (SD) nm.

We next employed real-time fluorescence intravital microscopy to study the uptake of albumin nanoparticles by neutrophils\textsuperscript{13}. Vascular inflammation was induced by intrascrotal injection of the pro-inflammatory cytokine tumour necrosis factor (TNF-\(\alpha\)) in mice. At 3 hr post-TNF-\(\alpha\) challenge, cremaster muscle was exposed, and neutrophils adherent to activated venular endothelial cells were monitored. Intravenous injection of Cy5-loaded albumin nanoparticles resulted in the nanoparticles being largely internalized by the leukocytes adherent to the inflamed venular endothelial cells, and to some extent by neutrophils slowly rolling along the vessel wall (Movie 1). However, nanoparticles were not internalized by the TNF-\(\alpha\) activated endothelium itself. To confirm that the nanoparticles were primarily internalized by neutrophils, we simultaneously intravenously infused an Alexa Fluor 488-labeled anti-mouse Gr-1 antibody\textsuperscript{13} and Cy5-loaded albumin nanoparticles. Anti-mouse Gr-1 antibody and albumin nanoparticles showed marked co-staining (Fig. 1a and Movie 2). In control experiments, non-immune isotype control antibody, IgG did not show a signal (Supplementary Fig. S4). To address whether albumin nanoparticles can also be
internalized by unstimulated neutrophils in the circulation, Cy5-loaded albumin nanoparticles were infused intravenously. Here Cy5-loaded albumin nanoparticles, we failed to detect Gr-1 positive neutrophils (Fig. 1b and Movie 3), indicating that only adherent neutrophils were able to internalize the nanoparticles. We also examined nanoparticle internalization by adherent monocytes, another phagocytic cell involved in inflammation\textsuperscript{17}. At 3 hr post-intrascrotal injection of TNF-\(\alpha\), Alexa Fluor 488-labeled anti-mouse F4/80 antibody\textsuperscript{17} (which marks for monocytes) and Cy5-loaded albumin nanoparticles were infused intravenously, and monitored. Adherent monocytes, unlike neutrophils, did not internalize albumin nanoparticles (Fig. 1c-d and Movie 4).

To investigate essential determinants of nanoparticle internalization, we compared the uptake of three different types of nanoparticles by activated neutrophil. In the first two, BSA nanoparticles were made by ethanol-induced albumin desolvation\textsuperscript{16,18} to denature albumin, a process followed by albumin cross-linking to form stable particles (Fig. 2a). Albumin nanoparticles were then either incorporated with fluorescent dye (Cy5-loaded albumin nanoparticles shown in Fig. 1) or their surface was chemically conjugated with Alexa Fluor 647 by carboxyl-amine reaction that forms covalent bonds between Alexa Fluor 647 and albumin nanoparticles (Alexa Fluor 647-conjugated albumin nanoparticles)\textsuperscript{19}. Also we fabricated nanoparticles in which yellow-green fluorescence polystyrene nanoparticles with diameter of 100 nm were coated with native BSA (albumin-conjugated polystyrene nanoparticles)\textsuperscript{19}. Comparing the uptake of these two types of albumin nanoparticles by Gr-1 positive neutrophils following intravenous infusion at 3 hr after intrascrotal injection of TNF-\(\alpha\), we observed that Alexa Fluor 647-conjugated albumin nanoparticles were internalized by the adherent
neutrophils and showed characteristic punctual distribution in the cytosol whereas Cy5-loaded albumin nanoparticles showed diffuse fluorescence throughout the cell (Fig. 2b-c). The latter observation was attributed to the release of Cy5 dye bound non-covalently to nanoparticles following nanoparticle internalization. The punctual structures in the cytosol represented individual or aggregated nanoparticles (Fig. 2c and Movie 5), presumably into lyso-endosomal compartments. Conjugation of Cy5 to albumin nanoparticles also exhibited the same punctual structures in adherent neutrophils as Alexa Fluor 647-conjugated albumin nanoparticles (Fig. 2c-d); thus, dye conjugation method prevents dye dispersal following nanoparticle internalization. Comparing the fluorescence intensities of internalized Cy5-loaded nanoparticles with Cy5-conjugated nanoparticles, uptake efficiency of two types of albumin nanoparticles was similar (Fig. 2d). Further, we observed that the general morphology of the adherent neutrophils internalizing either type of nanoparticle was the same and cells had similar surface area of 54 ± 6 (mean ± SD) µm². Unlike nanoparticles made from denatured albumin, native albumin-conjugated polystyrene nanoparticles remained bound to the surface of neutrophils without internalizing (Fig. 2e and Movie 6). We also did not observe uptake of albumin itself following intravenous infusion of Cy5 conjugated to albumin (Fig. 2f). As quantified by multiple images, 95% of all adherent neutrophils similarly internalized either dye-loaded or dye-conjugated albumin nanoparticles. In contrast, neither albumin-conjugated polystyrene particles nor Cy5-conjugated albumin was internalized by the adherent neutrophils (Fig. 2g).

FcγRs bind IgG-opsonized particles and denatured proteins, and activate endocytosis⁴. Thus, we investigated whether nanoparticles made of denatured
albumin could be internalized through FcγR signaling. Using neutrophils obtaining from FcγRIII−/− mice, we observed that uptake of albumin nanoparticles was significantly reduced compared to wild-type (WT) (Fig. 3a). On measuring fluorescence intensity of Cy5-loaded albumin nanoparticles per neutrophil, we obtained a distribution of nanoparticle uptake per neutrophil (Fig. 3b). FcγRIII contributed to ~50% of total uptake of albumin nanoparticles (Fig. 3g), consistent with the role of FcγR signaling as a mechanism of immune complex internalization by neutrophils. The basis of residual uptake is unclear but may involve other Fcγ receptors. Macrophage antigen-1 (Mac-1 or αMβ2 integrin) and lymphocyte function-associated antigen-1 (LFA-1 or αLβ2 integrin) mediate neutrophil adhesion during vascular inflammation and denatured albumin binds to Mac-1 and may contribute to uptake of denatured proteins; however, we observed that deletion of Mac-1 and LFA-1 had no effect on uptake of albumin nanoparticles (Fig. 3c-g).

We next examined whether albumin nanoparticles loaded with the Syk inhibitor, piceatannol, could reverse the TNF-α-mediated firm adhesion of neutrophils to venular endothelial cells, and thus mitigate inflammation. Syk signaling is crucial in the mechanism of ‘outside-in’ integrin signaling that mediates β2 integrin-dependent neutrophil adhesion, spreading, and migration. Piceatannol selectively inhibits Syk activity but it is an ineffective due to water solubility. We investigated whether piceatannol could be loaded into albumin nanoparticles for delivery into adherent neutrophils (Supplementary Fig. S5). In this study, most neutrophils adhered to the endothelium, although few rolling neutrophils were also seen (Fig. 4a and Movie 7). Intravenous infusion of piceatannol-loaded albumin nanoparticles, 1 mg/kg body weight
of piceatannol (50 µM), significantly reduced the number of adherent neutrophil and concomitantly increased the number of rolling cells (Fig. 4b-c and Movie 8). In controls, albumin nanoparticles alone had no effect (Fig. 4d).

To investigate further the mechanisms of action of piceatannol-loaded albumin nanoparticles, the flow chamber assay was used in which mouse neutrophils interacted with a monolayer of TNF-α-activated mouse lung endothelial cells under shear condition. In control experiments, Cy5-loaded albumin nanoparticles were internalized by Gr-1 positive neutrophils as in mouse venular studies above. The nanoparticle signal was slightly increased in neutrophils stimulated with N-formyl methionyl peptide, formyl-methionyl-leucyl phenylalanine (fMLF) (Supplementary Fig. S6). However, treatment of neutrophils with piceatannol-loaded albumin nanoparticles, 800 µg/ml (200 µM as piceatannol) under shear condition markedly reduced β2 integrin-mediated neutrophil spreading and migration across TNF-α-activated endothelial cells and inhibited neutrophil adhesion (Fig. 4e). Thus, piceatannol-loaded albumin nanoparticles functioned by inhibiting β2 integrin-mediated ‘outside-in’ signaling through Syk signaling, consistent with the known function of Syk. Syk phosphorylation in fMLF-stimulated neutrophils was also abrogated in neutrophils internalizing piceatannol-loaded albumin nanoparticles (Fig. 4f) indicating that the drug loaded into nanoparticles blocked Syk activity. We performed the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to eliminate possible drug toxicity effect. Incubating neutrophils with piceatannol-loaded albumin nanoparticles, 800 µg/ml (200 µM as piceatannol), did not affect cell viability (Fig. 4g). Thus, piceatannol-loaded albumin nanoparticles inhibited
Syk phosphorylation, and thereby impaired β2 integrin-mediated ‘outside-in’ signaling required for neutrophil spreading and migration.

Excessive accumulation of neutrophils in lungs is a major factor in the pathogenesis of acute lung injury associated with sepsis\textsuperscript{25}. We showed that β2 integrin-dependent neutrophil adhesion to lung endothelial cells\textsuperscript{26} contributes to acute lung injury\textsuperscript{4}. Thus, we determined whether piceatannol-loaded albumin nanoparticles could ameliorate lung neutrophil infiltration induced by intraperitoneal injection of LPS (lipopolysaccharide, 10 mg/kg body weight). Treating mice with piceatannol-loaded albumin nanoparticles, 4.3 mg/kg body weight as piceatannol (200 µM in blood), 2 hr after LPS challenge, markedly reduced lung tissue myeloperoxidase (MPO) activity, an indication of reduced neutrophil sequestration (Fig. 4h, Fig. 4i, and Supplementary Fig. S7). Infiltration of both neutrophils and monocytes determined by bronchoalveolar lavage (BAL) was also reduced by treating mice with piceatannol-loaded albumin nanoparticles (4.3 mg/kg body weight as piceatannol) (Fig. 4j). Comparison of MPO activity in LPS-induced lung inflammation after administration of piceatannol-loaded albumin nanoparticles and piceatannol (free drug) alone also showed that piceatannol-loaded nanoparticles were far more efficacious than piceatannol (Fig. 4k). Since as shown above albumin nanoparticles are preferentially internalized by neutrophils \textit{in vivo}, these results demonstrate that impaired neutrophil infiltration in lungs by piceatannol-loaded albumin nanoparticles is essential for inhibiting monocyte infiltration. These results also showed the utility of albumin nanoparticle loading of piceatannol for the treatment of acute lung injury.
In summary, we demonstrated an albumin nanoparticle approach for the delivery of drugs into inflammatory neutrophils adherent to endothelial cells that is in part dependent on FcγRIII signaling. Adhesion of neutrophils to activated endothelial cells was required for the internalization of albumin nanoparticles. Since FcγRs are highly expressed in adherent neutrophils during inflammation and vascular diseases, nanoparticles made of denatured albumin can be used to target inflammatory neutrophils while sparing the essential host-defense function of circulating neutrophil. This strategy limits the undesirable effects of globally blocking the essential bactericidal function of neutrophils. Further, we suggest the feasibility of using albumin nanoparticles to target activated neutrophils without conjugating ligands or antibodies to the nanoparticle surface. The results hence provide the proof-of-concept of a novel nanoparticle-based therapeutic approach for targeting activated neutrophils to treat a range of inflammatory disorders.
Methods

Preparation of albumin nanoparticles loaded with fluorescent dyes or piceatannol. BSA (bovine serum albumin) nanoparticles were prepared by the desolvation technique (Supplementary Fig. S1). BSA was first dissolved at a concentration of 20 mg/ml in deionized water. BSA solution, 1 ml, was used to make nanoparticles by the continuous addition of 3.5 ml of ethanol under stirring (650 rpm) for 10 min at RT. In some experiments, BSA solution at 20 mg/ml (1 ml) was mixed and incubated with 40 µl of Cy5 dye (5 mg/ml) in chloroform for 1 hr, followed by desolvation with ethanol. To make piceatannol-loaded albumin nanoparticles, 1 ml of 20 mg/ml of BSA solution was incubated with 1 mg of piceatannol dissolved in DMSO for 1 hr. To form stable albumin nanoparticles with or without a dye or piceatannol, BSA molecules were cross-linked by adding 20 µl of 0.2% glutaraldehyde in the suspension. The suspension was stirred overnight at RT. Nanoparticle suspension was centrifuged at 14,000 rpm for 20 min at 4°C. After drying albumin nanoparticles, we obtained 80-90% albumin to form the nanoparticles. The nanoparticle pellet was re-suspended in water or phosphate-buffered saline, pH 7.4 for the study.

To measure the efficiency of piceatannol incorporation in BSA nanoparticles, different concentrations of piceatannol were added in the initial albumin solution. After centrifugation of suspension of piceatannol-loaded BSA nanoparticles at 14,000 rpm at 4°C for 30 min, the supernatant (containing unbound piceatannol) was collected and centrifuged using Microcon (10-kD cut-off) to separate unbound piceatannol from free BSA molecules. Piceatannol molecules were quantified by measuring the absorbance at 328 nm as shown in Supplementary Fig. S5. The loading yield of piceatannol in
albumin nanoparticles was calculated by the following equation: Loading yield (%) = (Drug used- unloaded drug)/Drug used. After drying and weighting piceatannol-loaded albumin nanoparticles, we obtained 10-14 wt% of piceatannol loaded in albumin nanoparticles.

To conjugate covalently Alexa Fluor-647 or Cy5 dye to albumin nanoparticles, we used the carboxyl-amine reaction between dye and albumin. After albumin nanoparticles were made using the desolvation method as described above, we mixed Alex Fluor 647-NHS with albumin nanoparticles, and incubated the mixture for 2 hr at RT. We centrifuged albumin nanoparticles to remove free dye molecules to obtain Alexa Fluor 647-conjugated albumin nanoparticles.

**Real-time fluorescence intravital microscopy.** In vivo intravital microscopy was performed as described. TNF-α (0.5 µg in 250 µl saline) was intrascrotally injected into wild-type (WT) or knockout mice. At 3 hr after TNF-α injection, mice were anesthetized with intraperitoneal injection of the mixture of ketamine (80 mg/kg), xylazine (2 mg/kg), and acepromazine (2 mg/kg) and maintained at 37°C on a thermo-controlled rodent blanket and a tracheal tube was inserted. After excision of the scrotum, cremaster muscles were exteriorized on the intravital microscope table. The cremaster preparation was superfused with thermo-controlled (37°C) and aerated (95% N₂, 5% CO₂) bicarbonate-buffered saline during the experiment. Fluorescently-labeled albumin nanoparticles (100 µg) in 100 µl of saline were infused through a cannula placed in a jugular vein, followed by infusion of the Alexa Fluor 488-labeled anti-mouse Gr-1 antibody (0.05 µg/g body weight). Rolling and adherent neutrophils were monitored in an area of 0.02 mm² in inflamed cremaster muscle venules. Images were recorded
using an Olympus BX61W microscope with a 60 x /1.0 NA water immersion objective lens and a high speed camera (Hamamatsu C9300) connected to an intensifier (Video Scope International). To study the therapeutic effects of piceatannol-loaded albumin nanoparticles, the Alexa Fluor 488-labeled anti-mouse Gr-1 antibody was intravenously infused, followed by infusion of either piceatannol-loaded albumin nanoparticles or control albumin nanoparticles (150 μg of albumin nanoparticles containing 50 μM piceatannol). At 30 or 60 minutes after infusion of nanoparticles, rolling and adherent neutrophils were monitored. In some experiments, an Alexa Fluor 488-labeled anti-mouse F4/80 antibody (2 µg/mouse) was infused to monitor monocytes. Neutrophils that remained stationary or did not exceed displacement of > 8 µm for at least 30 sec were considered adherent. To quantify neutrophil rolling and adherence, each vessel was monitored for > 3 min. Approximately 20 venules from 3 mice were monitored for each group of experiments. Data analysis was performed using Slidebook 5.5 (Intelligent Imaging Innovations). To quantify fluorescence signals, we integrated fluorescence intensities of albumin nanoparticles internalized into neutrophils using the software, and analyzed the distribution of nanoparticle uptake in neutrophils.

In vitro cytotoxicity, Syk phosphorylation, flow cytometric analysis, flow chamber assay, and acute lung inflammation model are presented in Supplementary Methods.

**Statistical Analysis:** Data are expressed as mean ± SD or SEM. Data were analyzed using one-way ANOVA (multiple groups) or Student t-test (two groups) of Origin 8.5, with p values <0.05 were considered significant.
FIGURE LEGENDS

Figure 1. Uptake of albumin nanoparticles by adherent neutrophils in venules. Intravital microscopy of mouse cremaster muscle venules demonstrates that Cy5-loaded albumin nanoparticles (red) are internalized by activated neutrophils following TNF-α- (0.5 µg/mouse) (a) or during surgical stress-induced (b) vascular inflammation in mice. Neutrophils (green) were visualized by intravenous infusion of Alexa Fluor 488 anti-mouse Gr-1 antibody. In the TNF-α challenge group, the nanoparticles were intravenously infused 3 hr post-intrascrotal injection of TNF-α (0.5 µg/mouse). c, Monocytes (green) were visualized by infusion of Alexa Fluor 488 anti-mouse F4/80 antibody also 3hr following TNF-α-induced vascular inflammation. Scale bars, 20 µm. d, Percentage of neutrophils and monocytes internalizing albumin nanoparticles. In all experiments, 100 µg fluorescent dye-labeled albumin nanoparticles was infused intravenously per mouse. All data represent mean ± SEM (n = 13-20 vessels in 3 mice per group).

Figure 2. Characteristics of internalization properties of different types of albumin nanoparticles. a, Formulation of three types of fluorescently-labeled albumin nanoparticles studied. Albumin nanoparticles made from denatured albumin were either loaded with Cy5 (Dye-loaded Alb nanoparticle) or the particle surface was chemically conjugated with Alex Fluor 647 or Cy5 (Dye-conjugated Alb nanoparticle) as described in Methods. The third type is polystyrene nanoparticles (also with diameter of 100 nm) made by conjugating with native albumin (Alb-conjugated polystyrene nanoparticle). Intravital microscopy was performed in mice as described in Fig. 1. Cy5-loaded (b) and Alex Fluor 647-conjugated (c) albumin nanoparticles (red) were internalized by Gr-1-
positive neutrophils (green). Scale bars, 10 µm. 

**d**, Quantitative analysis of uptake of Cy5-loaded and Cy5-conjugated albumin nanoparticles was carried out by measuring fluorescence intensity per neutrophil. Inset images show Cy5-loaded and Cy5-conjugated albumin nanoparticles (red) internalized by neutrophils (green). 

**e**, Native albumin-conjugated polystyrene nanoparticles (green) were bound to the neutrophil surface (red). 

**f**, Cy5-conjugated native albumin (red) was not internalized by Gr-1-positive neutrophils (green). Scale bars, 10 µm. 

**g**, Quantitative analysis of percentage of Gr-1-positive neutrophils internalizing the 3 types of nanoparticles and Cy5-labeled albumin. Results are shown as mean ± SEM (n = 13-20 vessels in 3 mice per group). ND = not detected.

**Figure 3. Contribution of FcyRIII mechanism in mediating albumin nanoparticle internalization.** 

- **a-f**, Intravital microscopy of cremaster muscle inflamed venules was performed in wild-type (WT) and FcyRIII+/− (a), Mac-1−/− (c), and LFA-1−/− mice (e). Scale bars, 20 µm. Cy5-loaded albumin nanoparticles (red) were intravenously infused 3 hr after the intrascrotal injection of TNF-α (0.5 µg/mouse). Histograms of Cy5-loaded albumin nanoparticles internalized by neutrophils in WT and FcyRIII+/− (b), Mac-1−/− (d), and LFA-1−/− mice (f) were obtained from more than 500 neutrophils in 3 mice per group. Integrated fluorescence intensities of nanoparticles in individual polymorphonuclear neutrophils (PMNs).

**g**, Percentage albumin nanoparticle uptake in WT versus knockout mice in each group based on data from (b, d, and f). # P<0.0001 vs. WT mice after ANOVA and Dunnett’s test. NS, not significant.

**Figure 4. Therapeutic activity of albumin nanoparticles in vascular inflammation and lung injury models.** 

- **a-d**, Intravital microscopy showing rolling and adhesion of
neutrophils (green) monitored by intravenous infusion of Alexa Fluor 488-conjugated antibodies in mice before (a) and at 1 hr post-intravenous infusion of piceatannol-loaded albumin nanoparticles (50 μM piceatannol) (b) in the same mouse. hh:mm:ss in (a) and (b) represent time series of images. White lines show trajectories of neutrophils detaching from endothelial cells. Scale bars, 20 µm. c, Quantification of neutrophil adhesion and rolling in TNF-α-activated cremaster muscle vessels at baseline and at 30 and 60 min after intravenous infusion of piceatannol-loaded albumin nanoparticles. Data represent mean ± SEM (n = 21 venules in 3 mice). # and * represent P <0.001 and <0.001 vs. pre-infusion of piceatannol-loaded albumin nanoparticles after ANOVA and Dunnett’s test. d, Albumin nanoparticles without piceatannol loading were tested as controls and quantified as described in (c). Data represent mean ± SEM (n = 18 venules in 3 mice). e, Mouse neutrophils were pre-treated with 800 µg/ml albumin nanoparticles (NP) or piceatannol-loaded albumin nanoparticles (Pic-NP, 200 µM as piceatannol), and stimulated with N-formyl-methionyl-leucyl-phenylalanine (fMLF). Flow chamber assay at fixed shear representing venous shear (1 dyne/cm²) was performed as described in Supplementary Methods. The number of adherent neutrophils (either spread or round) was quantified during the 10-min recording period. Data represent mean ± SD (n = 3). f, Mouse neutrophils were plated on fibrinogen-coated surfaces and incubated with RPMI culture media, 800 µg/ml albumin nanoparticles (NP) or piceatannol-loaded albumin nanoparticles (Pic-NP, 200 µM) in the presence of 50 ng/ml TNF-α for 30 min. Lysates were immunoblotted with anti-phospho Syk-Tyr525/526 antibody. Data represent mean ± SD (n = 3). ** P < 0.01 and *** P<0.001 vs. unstimulated cells after ANOVA and Dunnett’s test. g, Unstimulated or fMLF-stimulated mouse neutrophils were
treated with 800 µg/ml albumin nanoparticles (NP) or piceatannol-loaded albumin nanoparticles (Pic-NP, 200 µM as piceatannol) for 1 hr. MTT assay was performed as described in Methods. Cell viability is presented as mean ± SD (n = 3). ** P<0.01 vs. unstimulated cells after ANOVA and Dunnett’s test. Cell viability was not different among any experimental group. **h-k, Effects of piceatannol-loaded albumin nanoparticles on LPS-induced lung inflammation (See Methods for details). The line above the figures describes the protocol. Lung myeloperoxidase (MPO) activity (h) and number of neutrophils sequestered in lungs (i) before and after intravenous infusion of piceatannol-loaded albumin nanoparticles. Data represent mean ± SD (n = 3). * P<0.001 vs control after ANOVA. **j, Leukocyte number in bronchoalveolar lavage (BAL) after intravenous infusion of albumin nanoparticles (Alb-Nano) and piceatannol-loaded albumin nanoparticles (Pic-Alb Nano) with piceatannol amount at 4.3 mg/kg body weight. * P<0.01 and ** P<0.05. **k, Neutrophil infiltration in LPS-induced acute lung inflammation assessed by MPO activity after intravenous infusion of piceatannol (Pic)-loaded albumin nanoparticles compared to free piceatannol, 4.3 mg/kg body weight. * P <0.05 vs. free piceatannol after Student t-test.
REFERENCES

1. Hu, G., Malik, A. B. & Minshall, R. D. Toll-like receptor 4 mediates neutrophil sequestration and lung injury induced by endotoxin and hyperinflation. *Crit. Care Med.* **38**, 194-201 (2010).

2. Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. *Science* **339**, 166-172 (2013).

3. Wang, Z., Tiruppathi, C., Cho, J., Minshall, R. D. & Malik, A. B. Delivery of nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae. *IUBMB Life* **63**, 659-667 (2011).

4. Xu, J. *et al.* Nonmuscle myosin light-chain kinase mediates neutrophil transmigration in sepsis-induced lung inflammation by activating beta2 integrins. *Nat. Immunol.* **9**, 880-886 (2008).

5. Wong, C. H., Heit, B. & Kubes, P. Molecular regulators of leucocyte chemotaxis during inflammation. *Cardiovasc. Res.* **86**, 183-191 (2010).

6. Phillipson, M. & Kubes, P. The neutrophil in vascular inflammation. *Nat. Med.* **17**, 1381-1390 (2011).

7. Wagner, D. D. & Frenette, P. S. The vessel wall and its interactions. *Blood* **111**, 5271-5281 (2008).

8. Lockwood, C. M. *et al.* Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation. *Clin. Immunol.* **93**, 93-106 (1999).

9. Sharar, S. R., Winn, R. K., Murry, C. E., Harlan, J. M. & Rice, C. L. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. *Surgery* **110**, 213-219 (1991).

10. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. *Nat. Rev. Drug Discov.* **9**, 615-627 (2010).

11. Farokhzad, O. C. & Langer, R. Impact of nanotechnology on drug delivery. *ACS Nano* **3**, 16-20 (2009).

12. Schroeder, A. *et al.* Treating metastatic cancer with nanotechnology. *Nat. Rev. Cancer* **12**, 39-50 (2012).

13. Hahm, E. *et al.* Extracellular protein disulfide isomerase regulates ligand-binding activity of alphaMbeta2 integrin and neutrophil recruitment during vascular inflammation. *Blood* **121**, 3789-3800 (2013).

14. Hidalgo, A. *et al.* Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. *Nat Med* **15**, 384-391 (2009).

15. Evans, R., Lellouch, A. C., Svensson, L., McDowall, A. & Hogg, N. The integrin LFA-1 signals through ZAP-70 to regulate expression of high-affinity LFA-1 on T lymphocytes. *Blood* **117**, 3331-3342 (2011).

16. Weber, C., Kreuter, J. & Langer, K. Desolvation process and surface characteristics of HSA-nanoparticles. *Int. J. Pharm.* **196**, 197-200 (2000).

17. Sumagin, R., Prizant, H., Lomakina, E., Waugh, R. E. & Sarelius, I. H. LFA-1 and Mac-1 define characteristically different intralumenal crawling and emigration patterns for monocytes and neutrophils in situ. *J. Immunol.* **185**, 7057-7066 (2010).
Bull, H. B. & Breese, K. Interaction of Alcohols with Proteins. *Biopolymers* **17**, 2121-2131 (1978).

Wang, Z., Tiruppathi, C., Minshull, R. D. & Malik, A. B. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. *ACS Nano* **3**, 4110-4116 (2009).

Chen, K. *et al*. Endocytosis of soluble immune complexes leads to their clearance by Fc gammaRIIB but induces neutrophil extracellular traps via Fc gammaRIIA in vivo. *Blood* **120**, 4421-4431 (2012).

Indik, Z. K., Park, J. G., Hunter, S. & Schreiber, A. D. The molecular dissection of Fc gamma receptor mediated phagocytosis. *Blood* **86**, 4389-4399 (1995).

Zarbock, A., Lowell, C. A. & Ley, K. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. *Immunity* **26**, 773-783 (2007).

Geahlen, R. L. & McLaughlin, J. L. Piceatannol (3,4,3',5'-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. *Biochem. Biophys. Res. Commun.* **165**, 241-245 (1989).

Wisel, S. *et al*. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. *J. Pharmacol. Exp. Ther.* **329**, 543-550 (2009).

Matthay, M. A. & Zemans, R. L. The acute respiratory distress syndrome: pathogenesis and treatment. *Annu. Rev. Pathol.* **6**, 147-163 (2011).

Lo, S. K., Everitt, J., Gu, J. & Malik, A. B. Tumor necrosis factor mediates experimental pulmonary edema by ICAM-1 and CD18-dependent mechanisms. *J. Clin. Invest* **89**, 981-988 (1992).

Nakatani, K. *et al*. Regulation of the expression of Fc gamma receptor on circulating neutrophils and monocytes in Kawasaki disease. *Clin. Exp. Immunol* **117**, 418-422 (1999).

**Acknowledgment:** This work was supported by 11SDG7490013 from American Heart Association and NIH K25HL111157 to Z.W., R01 HL109439 to J.C., and P01 P01HL77806 to A.B.M.

**Author Contributions:** Z.W., J.C., and A.B.M. designed the experiments and analyzed the data; Z.W. and J.L. carried out the experiments; Z.W., J.C., and A.B.M. wrote the manuscript.
Additional information

Supplementary information accompanying this paper can be found at www.nature.com/naturenanotechnology. Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/. Correspondence and requests for materials should be addressed to A. B. M.

Competing Financial Interests: The authors declare no competing financial interests.